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Introduction: Routine interventions in the practice of medicine often lack definitive evidence or 
are based on evidence that is either not high quality or of only modest-to-marginal effect sizes. 
An abnormal urinalysis in an elderly patient presenting to the emergency department (ED) with 
non-specific symptoms represents one condition that requires an evidence-informed approach 
to diagnosis and management of either asymptomatic bacteriuria or urinary tract infection (UTI). 
The emergency provider often will not have access to urine cultures, and the risks associated with 
antibiotic use in the elderly are not without potentially significant side effects.
Methods: We performed a historical and clinical review of the growing body of literature 
suggesting measurable differences in the systemic immune response manifest among patients with 
asymptomatic pyuria and UTI, including increases in the pro-inflammatory cytokine interleukin-6 and 
the acute phase reactant procalcitonin. 
Results: Serum procalcitonin, a peptide that undergoes proteolysis into calcitonin, has been 
demonstrated to quickly and reliably rise in patients with severe bacterial infections, and may serve 
as a potentially sensitive and specific marker for identification of bacterial illness. 
Conclusion: In the absence of validated risk scores for diagnosing UTI in elderly patients presenting 
to the ED, there may be a role for the use of procalcitonin in this patient population. [West J Emerg 
Med. 2019;20(4)573-577.]
INTRODUCTION
Evidence-Based to Evidence-Informed Practice: The 
Clinical Reality 
The evolution from eminence-based to evidence-
based care has come to define bedside emergency medicine 
(EM), with rigorous skepticism and scholarly consideration 
accelerated by the power of global connectivity.1 Where 
anecdote and opinion once drove therapy, clinicians now 
approach clinical conundrums with deliberate reflection, 
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expecting – and at times demanding – ever-higher proof of 
perfection prior to implementing or incorporating therapies, 
tests, or approaches into their own practice. Such cogitation 
ensures excellence and safety and avoids pitfalls of over-
adoption or confounding. Sackett originally defined this 
approach as evidence-based medicine, or the “use of current 
best evidence in making decisions about the care of individual 
patients...integrating individual clinical expertise” and 
honoring patients’ values and preferences.2 Unfortunately, 
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many of our daily decisions are made in a space devoid of 
definitive data.3-8 
We thus are required to transition from the ideals of 
evidence-based medicine into the real and pragmatic world of 
evidence-informed medicine. It is at this precipice of real-world 
practice—where often studies and statistics do not exist, are not 
of high quality, or are of modest-to-marginal effect sizes—that 
we change, where we push forward the boundaries of care, and 
develop not only experience but the very questions that will 
define the next advances in EM. With this in mind, we sought to 
explore the clinical realities of the assessment and treatment of 
abnormal urinalyses in the elderly patient presenting with non-
specific symptoms to the emergency department (ED).
METHODS
We performed a historical and clinical review of the current 
literature on urinary tract infection (UTI) focusing on identifying 
and summarizing key trends relevant to the diagnosis of abnormal 
urinalyses in elderly patients with non-specific symptoms with a 
specific emphasis on the biomarker procalcitonin.
RESULTS
Asymptomatic Bacteriuria: Historical Perspective
Asymptomatic bacteriuria was first identified in the mid-
1950s, when a series of autopsy reports identified chronic 
pyelonephritis as a common cause of renal failure, despite the fact 
that none of the deceased individuals had been diagnosed with a 
urinary tract infection while alive.9 Such findings led researchers 
to declare, “there is now clear evidence that bacteriuria is one 
of the commonest human infections, that it may be chronic and 
persistent, that it may influence structure and function outside 
of the urinary tract, and that it plays an important role in disease 
from the cradle to the grave—from prematurity to hypertension 
and renal failure.”10 Since these observations, decades of 
antibiotics have been administered with frequency through 
the mouths, veins, and bladders of asymptomatic patients, all 
while several studies conclusively demonstrated that treatment 
of asymptomatic bacteriuria not only lacks benefit, but likely 
increases the short-term risk of pyelonephritis.11 
Asymptomatic Bacteriuria: Clinical Pearls in the 
Emergency Department
Asymptomatic bacteriuria is a microbiologic diagnosis 
defined as >105 colony-forming units per milliliter (cfu/mL) 
bacteria identified in two consecutive voided urine specimens 
(only one specimen needed for males).12 It is incredibly common, 
affecting greater than 20% of healthy, elderly, community-
dwelling women, and reaching a prevalence as high as 50% 
in institutionalized elderly females, and 100% in patients with 
indwelling catheters.13 In the ED, without access to culture 
information, emergency providers are thus not confronted with 
asymptomatic bacteriuria, but rather asymptomatic pyuria, an 
even more prevalent and low-yield urinalysis usurper. 
The clinical conundrum of the abnormal urinalysis in 
an elderly patient presenting with non-specific symptoms is 
a common occurrence.14 While it is well-known that UTIs 
can cause malaise and mental status changes in elderly 
populations,15 consistent clinical data suggest that the 
overwhelming percentage of “positive” urinalyses (UA) 
represent asymptomatic bacteriuria, and are neither truly 
indicative of UTI nor related to the patient’s non-specific 
complaints.16 Additionally, fixating on the “positive” UA can 
often cause clinicians to reach premature diagnostic closure 
and stop further investigations. Unfortunately, determining 
which UAs represent constitution-influencing infection and 
which are simple asymptomatic presentations is a difficult task 
in the ED, particularly when the patient lacks the cognitive 
or physical ability to relay typical symptoms such as dysuria, 
urinary frequency, or hesitancy. 
Knowing that antibiotic treatment is of no value in non-
pregnant patients with simple asymptomatic bacteriuria,11,12 
we strive to limit such unnecessary antimicrobials, which also 
bring risk of allergic reaction, increased antibiotic resistance, 
and iatrogenic injury ranging from Clostridium difficile colitis 
to renal injury. 
Despite compelling data that treatment of asymptomatic 
bacteriuria lacks benefit, and growing evidence that non-
specific symptoms in the elderly are generally not caused by 
UTIs,16 these patients are overwhelmingly exposed to broad 
spectrum agents initiated in the ED or upon admission to the 
hospital.17,18 It can be difficult for the emergency provider to 
avoid incorporating into the diagnostic framework the need 
for antibiotic stewardship with the real concerns of disease 
progression or missed infection treatment metrics. Even when 
restraint wins out in the ED, diagnostic equipoise often drives 
inpatient teams to start antibiotics. Strikingly, well-done surveys 
demonstrate that nearly half of physician respondents prescribe 
antibiotics for asymptomatic bacteriuria despite knowing a UA 
demonstrates asymptomatic bacteriuria and not true infection.19 
When clinicians are unable to elicit information on lower 
urinary tract symptoms from elderly patients with dementia, 
advanced cerebrovascular disease, or other impairments 
resulting in communication barriers, they are likely to initiate 
antimicrobial therapy in a well-intentioned effort to prevent 
progression and worsening infectious outcomes with anecdote 
of improvement perpetuating such practice.20
Systemic Immune Response
Recognizing the difficulty in distinguishing true infection 
from asymptomatic bacteriuria, multiple authors have 
attempted to investigate differences in systemic immune 
response among these cohorts. In 2011, a group of researchers 
compared the levels of various inflammatory markers in 
urine samples before and after inoculation with Escherichia 
coli, noting a substantial increase in both white blood cells 
and polymorphonuclear neutrophils, a not uncommon 
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phenomenon in lab results seen in the ED.21 Interestingly, 
however, levels of interleukin-6 (IL-6), a pro-inflammatory 
cytokine that is not only an acute phase reactant but also one 
of the major regulators of acute phase protein synthesis,22,23 
remained unchanged in this study.21 The authors suggested that 
these findings support the hypothesis that a less-robust host 
immune response occurs among patients with asymptomatic 
bacteriuria compared to those with symptomatic infection.
A subsequent study exploring the role of IL-6 and 
heparin binding-protein (HBP), a protein released from 
activated neutrophils during infection24 and previously shown 
to be associated with UTIs,25 a 2016 investigation enrolled 
asymptomatic, elderly, nursing home residents and matched 
them with patients living in the community or at nursing 
homes with symptomatic UTI.26 In this study, urinary IL-6, but 
not HBP, reliably distinguished between patients with cystitis 
or asymptomatic bacteriuria, adding further to the growing 
observational literature that there is a fundamental and 
measurable difference in the body’s immune reaction in cases 
of true infection compared to colonization.26 
Procalcitonin and Urinary Tract Infection
Perhaps one of the most hotly debated acute phase reactants, 
procalcitonin, is the latest diagnostic darling in inpatient circles. 
Procalcitonin (the biologic precursor to calcitonin) reaches 
measurable serum concentrations quickly and reliably in the 
setting of bacterial infection.27-29 Dozens of trials have reliably 
demonstrated procalcitonin’s strong performance in decision 
support for antibiotic initiation or cessation; however, in the 
most salient ED investigation—the Procalcitonin Consensus 
Trial (ProACT) —procalcitonin failed miserably in limiting 
unnecessary antibiotic use.30 Notably, however, such failure 
seemed more a function of clinician fears of untreated infection 
rather than a shortcoming of the test itself, an idiosyncrasy noted 
many times over in a myriad of editorials following publication 
of ProACT. The recently published HI-TEMP trial, however, 
applied PCT across a heterogeneous population and found no 
benefit in decreasing antibiotic use or significantly decreasing 
patient-oriented endpoints.31 As many respondents to ProACT 
argued, though – and the trial authors seemed to agree with – the 
combination of this reassuring objective test with a concerted 
effort to limit unnecessary antibiotic use, or an antibiotic 
stewardship program, could be more effective in harnessing the 
diagnostic value of procalcitonin.32-34 
DISCUSSION
We suggest that a considered and nuanced synthesis of 
this inflammatory marker in a well-defined clinical context 
is supported by a vibrant body of literature suggesting a role 
for procalcitonin in the diagnosis of true UTI. In one bench 
study, procalcitonin reliably increased with worsening urinary 
tract disease.35 Additionally, one comprehensive review found 
procalcitonin to be a “key marker” in children with UTI.36 When 
operationalized, serum procalcitonin was a good predictor of 
disease severity in a meta-analysis of prospective pediatric 
clinical trials of UTIs.37 More recently, a randomized controlled 
trial (RCT) out of Switzerland randomized patients presenting to 
the ED with a UTI to a procalcitonin-pyuria-based (PCT-pyuria) 
algorithm or current guidelines (control group) for initiation and 
duration of antibiotic therapy.38 In the intention-to-treat analysis, 
cumulative 90-day exposure to antibiotics was shorter in the 
PCT-pyuria group compared to the control, although with no 
changes in mortality and reinfections. In a 2015 Cochrane review 
assessing procalcitonin for diagnosing acute pyelonephritis in 
pediatric patients,39 there were limited studies at the time of 
the review and marked heterogeneity of the included studies 
to recommend it for daily practice, although procalcitonin 
performed significantly better for ruling-in pyelonephritis 
compared to erythrocyte sedimentation rate or C-reactive protein. 
It is important to note that procalcitonin can be elevated in 
any acute infectious circumstance and is not specific to a UTI. 
Therefore, an elevated procalcitonin level should not be equated 
to UTI and does not clinch the diagnosis of UTI. Pyuria in the 
setting of an elevated procalcitonin level may still represent 
asymptomatic bacteriuria with an alternate infectious process 
(i.e., meningitis, bacteremia, etc.). Clinicians should be cautious 
to avoid premature diagnostic closure in this circumstance. 
Furthermore, it should be noted that PCT levels may not rise 
with localized infections (septic arthritis, localized abscess, etc.), 
steroid use, and atypical bacteria,40,41 and decisions regarding 
antimicrobial therapy should not be based solely on procalcitonin 
serum concentrations.
Procalcitonin for Urinary Tract Infection in the 
Emergency Department
The management morass of abnormal urinalyses in the 
elderly patient with nonspecific symptoms may represent an 
excellent opportunity for utilization of procalcitonin testing 
using an evidence-informed approach, ie, efforts undertaken in 
the absence of strict guiding data but supported and shepherded 
by complementary knowledge. Given the ambiguity of 
asymptomatic bacteriuria, a de-facto antibiotic stewardship 
effort is already underway in every hospital across the country, 
as well-meaning physicians strive to separate true infection from 
asymptomatic distractors. Where clinical complacency exists—
an afebrile, non-toxic-appearing patient in whom the desire to 
spare unnecessary antibiotic use conflicts with the compulsion 
to not allow an indolent infection run rampant—a procalcitonin-
augmented strategy might satisfy both imperatives.
This recommended strategy is not novel. As recently 
reported in the American Journal of Emergency Medicine, 
one retrospective analysis of UTIs found a negative predictive 
value of 91% for a low procalcitonin further bolstering 
the argument in favor of its use as an adjunct in the non-
initiation of empiric antibiotics.42 Even more compelling, a 
RCT of nearly 200 ED patients found that a procalcitonin-
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based algorithm reduced antibiotic exposure by 30% without 
negative effects on clinical outcomes.38 The introduction of 
procalcitonin in these departments served as a reliable and 
objective diagnostic marker and limited costly, harmful, and 
unnecessary exposure to antibiotics.
LIMITATIONS
The use of procalcitonin in the work-up of UTI in elderly 
patients with an abnormal urinalysis presenting with non-
specific symptoms requires further investigation ideally 
through a multicenter, RCT. Furthermore, this historical and 
clinical review was not systematic in its goal to describe the 
entirety of the use of procalcitonin; however, the purpose of 
this paper was to provide a succinct, narrative update of the 
latest research related to the use of biomarkers for diagnosing 
UTI for this patient population in the ED setting. 
CONCLUSION
Where definitive studies are lacking, nuance and rational 
integration of the literature is not only an option, but an 
imperative. The application of evidence-based medicine is at its 
easiest after large RCTs and rigorous analyses are popularized 
and widely disseminated. A true test of bedside Bayesianism, 
however, comes when the clinician is presented with clinical 
conundrums not yet thoroughly vetted and extensively analyzed. 
When no clear answer exists in the literature, we are forced 
to faithfully apply the best available knowledge to answer 
critical questions in real time in an ongoing attempt to correct 
shortcomings and pursue better care. No current rigorous trial 
has yet examined procalcitonin’s performance in this narrow and 
nuanced framework, but the collated and considered information 
available suggests that adding this simple test likely provides a 
much-needed diagnostic beacon and can safely lead to better care 
in real-world applications.
Address for Correspondence: Richard M. Pescatore, DO, Crozer-
Keystone Health Systems, Department of Emergency Medicine, 
1 Medical Center Blvd, Upland, PA 19013. Email: richard.
pescatore@crozer.org.
Conflicts of Interest: By the WestJEM article submission agreement, 
all authors are required to disclose all affiliations, funding sources 
and financial or management relationships that could be perceived 
as potential sources of bias. No author has professional or financial 
relationships with any companies that are relevant to this study. 
There are no conflicts of interest or sources of funding to declare.
Copyright: © 2019 Pescatore et al. This is an open access article 
distributed in accordance with the terms of the Creative Commons 
Attribution (CC BY 4.0) License. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1. Pescatore R, Salzman M, Cassidy-Smith T, et al. The benefits and 
risks of asynchronous education. Acad Med. 2015;90(9):1183. 
2. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based 
medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71-2.
3. Ioannidis JP. Why most published research findings are false. PLoS 
Med. 2005;2(8):e124. 
4. Ioannidis JP. Contradicted and initially stronger effects in highly cited 
clinical research. JAMA. 2005;294(2):218-28.
5. Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an 
analysis of 146 contradicted medical practices. Mayo Clin Proc. 
2013;88(8):790-8. 
6. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of 
very large treatment effects of medical interventions. JAMA. 
2012;308(16):1676-84. 
7. Fleming PS, Koletsi D, Ioannidis JP, et al. High quality of the 
evidence for medical and other health-related interventions was 
uncommon in Cochrane systematic reviews. J Clin Epidemiol. 
2016;78:34-42. 
8. Prasad V, Gall V, Cifu A. The frequency of medical reversal. Arch 
Intern Med. 2011;171(18):1675-6. 
9. Freedman LR. Chronic pyelonephritis at autopsy. Ann Intern Med. 
1967;66(4):697-710.
10. Kass EH. Pyelonephritis and bacteriuria. A major problem in 
preventive medicine. Ann Intern Med. 1962;56:46-53.
11. Nicolle LE. The paradigm shift to non-treatment of asymptomatic 
bacteriuria. Pathogens. 2016;5(2). 
12. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of 
America guidelines for the diagnosis and treatment of asymptomatic 
bacteriuria in adults. Clin Infect Dis. 2005;40(5):643-54. 
13. Nicolle LE. Asymptomatic bacteriuria. Curr Opin Infect Dis. 
2014;27(1):90-6. 
14. Frazee BW, Enriquez K, Ng V, et al. Abnormal urinalysis results are 
common, regardless of specimen collection technique, in women 
without urinary tract infections. J Emerg Med. 2015;48(6):706-11. 
15. Gupta K, Grigoryan L, Trautner B. Urinary tract infection. Ann Intern 
Med. 2017;167(7):ITC49-64. 
16. Caterino JM, Kline DM, Leininger R, et al. Nonspecific symptoms lack 
diagnostic accuracy for infection in older patients in the emergency 
department. J Am Geriatr Soc. 2019;67(3):484-92.
17. Gandhi T, Flanders SA, Markovitz E, et al. Importance of urinary tract 
infection to antibiotic use among hospitalized patients. Infect Control 
Hosp Epidemiol. 2009;30(2):193-5. 
18. Khawcharoenporn T, Vasoo S, Ward E, et al. Abnormal urinalysis 
finding triggered antibiotic prescription for asymptomatic bacteriuria in 
the ED. Am J Emerg Med. 2011;29(7):828-30. 
19. Lee MJ, Kim M, Kim N-H, et al. Why is asymptomatic bacteriuria 
overtreated?: A tertiary care institutional survey of resident 
physicians. BMC Infect Dis. 2015;15:289. 
20. Miller J. To treat or not to treat: managing bacteriuria in elderly 
Volume 20, no. 4: July 2019 577 Western Journal of Emergency Medicine
Pescatore et al. Evidence-Informed Practice—Diagnostic Questions in Urinary Tract Infections in the Elderly
people. CMAJ. 2001;164(5):619-20.
21. Grönberg-Hernández J, Hernández JG, Sundén F, Connolly J, 
Svanborg C, Wullt B. Genetic control of the variable innate immune 
response to asymptomatic bacteriuria. PloS One. 2011;6(11):e28289.
22. Castell JV, Gómez-Lechón MJ, David M, et al. Interleukin-6 is the 
major regulator of acute phase protein synthesis in adult human 
hepatocytes. FEBS Lett. 1989;242(2):237-9.
23. Gruys E, Toussaint MJ, Niewold TA, et al. Acute phase reaction and 
acute phase proteins. J Zhejiang Univ Sci B. 2005;6(11):1045-56. 
24. Linder A, Christensson B, Herwald H, et al. Heparin-binding protein: 
an early marker of circulatory failure in sepsis. Clin Infect Dis. 
2009;49(7):1044-50. 
25. Kjölvmark C, Påhlman LI, Åkesson P, et al. Heparin-binding protein: a 
diagnostic biomarker of urinary tract infection in adults. Open Forum 
Infect Dis. 2014;1(1):ofu004.
26. Kjölvmark C, Tschernij E, Öberg J, et al. Distinguishing asymptomatic 
bacteriuria from urinary tract infection in the elderly - the use of urine 
levels of heparin-binding protein and interleukin-6. Diagn Microbiol 
Infect Dis. 2016;85(2):243-8. 
27. Quadir AF, Britton PN. Procalcitonin and C-reactive protein as 
biomarkers for neonatal bacterial infection. J Paediatr Child Health. 
2018;54(6):695-9. 
28. Memar MY, Varshochi M, Shokouhi B, et al. Procalcitonin: the marker 
of pediatric bacterial infection. Biomed Pharmacother. 2017;96:936-43.
29. Taggart K, Nielsen S. Procalcitonin as a biomarker of bacterial 
infection. S D Med. 2016;69(8):370-1.
30. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use 
of antibiotics for lower respiratory tract infection. N Engl J Med. 
2018;379(3):236-49. 
31. van der Does Y, Limper M, Jie KE, et al. Procalcitonin-
guided antibiotic therapy in patients with fever in a general 
emergency department population: a multicentre non-inferiority 
randomized clinical trial (HiTEMP study). Clin Microbiol Infect. 
2018;24(12):1282-9.
32. Bremmer DN, Shively NR, Walsh TL. Procalcitonin-guided antibiotic 
use. N Engl J Med. 2018;379(20):1972. 
33. Spellberg B, Gaffin N. Procalcitonin-guided antibiotic use. N Engl J 
Med. 2018;379(20):1972-3. 
34. Pulia MS, Schulz LT, Fox BC. Procalcitonin-guided antibiotic use. N 
Engl J Med. 2018;379(20):1971-2. 
35. Xu RY, Liu HW, Liu JL, et al. Procalcitonin and C-reactive protein in 
urinary tract infection diagnosis. BMC Urol. 2014;14:45. 
36. Leroy S, Gervaix A. Procalcitonin: a key marker in children with 
urinary tract infection. Adv Urol. 2011;2011:397618. 
37. Mantadakis E, Plessa E, Vouloumanou EK, et al. Serum procalcitonin 
for prediction of renal parenchymal involvement in children with 
urinary tract infections: a meta-analysis of prospective clinical 
studies. J Pediatr. 2009;155(6):875-81.e1. 
38. Drozdov D, Schwarz S, Kutz A, et al. Procalcitonin and pyuria-
based algorithm reduces antibiotic use in urinary tract infections: a 
randomized controlled trial. BMC Med. 2015;13:104. 
39. Shaikh N, Borrell JL, Evron J, et al. Procalcitonin, C-reactive 
protein, and erythrocyte sedimentation rate for the diagnosis of 
acute pyelonephritis in children. Cochrane Database Syst Rev. 
2015;1:CD009185. 
40. Jereb M, Kotar T. Usefulness of procalcitonin to differentiate 
typical from atypical community-acquired pneumonia. Wien Klin 
Wochenschr. 2006;118(5-6):170-4. 
41. Butbul-Aviel Y, Koren A, Halevy R, et al. Procalcitonin as a diagnostic 
aid in osteomyelitis and septic arthritis. Pediatr Emerg Care. 
2005;21(12):828-32. 
42. Levine AR, Tran M, Shepherd J, et al. Utility of initial procalcitonin 
values to predict urinary tract infection. Am J Emerg Med. 
2018;36(11):1993-7. 
